A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC).

Trial Profile

A Phase II Study of NK012 in Sensitive Relapsed and Refractory Relapsed Small-Cell Lung Cancer (SCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs NK 012 (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Jun 2011 Planned End Date changed from 1 Feb 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
    • 24 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 04 Nov 2010 Planned End Date changed from 1 Sep 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top